摘要
目的比较阿立哌唑和奋乃静治疗老年期精神分裂症的疗效和安全性。方法将67例老年期精神分裂症患者随机分为两组,分别给予阿立哌唑与奋乃静治疗8周,并在治疗前及治疗后1,2,4,8周末采用简明精神病评定量表(BPRS)、副反应量表(TESS)分别评定疗效和不良反应。结果阿立哌唑、奋乃静治疗老年期精神分裂症的疗效差异无显著性(P>0.05),但阿立哌唑不良反应较奋乃静少而轻微。结论阿立哌唑治疗老年期精神分裂症疗效好、起效快、不良反应少。
Objective To explore the efficacy and safety of aripiprazole and perphenazine in the treatment of aged schizophrenia. Mehods 67 patients with aged schizophrenia were randomly assigned into aripiprazole group or perphenazine group respectively and treated for 8 weeks. The efficacy was assessed with Brief Psychiatric Rating Scale （BPRS）, and the side effect was evaluated by Treatment Emergent Sideeffect Scale （TESS）. Results There was no significant difference in the efficacy between aripiprazole and perphenazine, but the side effects induced by aripiprazole were fewer and milder. Conclusion Aripiprazole is an effective and safe drug in the treatment of aged schizophrenia.
出处
《中国药业》
CAS
2007年第7期44-45,共2页
China Pharmaceuticals
关键词
阿立哌唑
奋乃静
老年期精神分裂症
疗效
aged schizophrenia
aripiprazole
pevphenazine
curative effect
